<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hoyle, Brian</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Maertens, Johan</style></author><author><style face="normal" font="default" size="100%">Hope, William</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Isavuconazole Safe, Effective in Treatment of IA in Patients With Renal Insufficiency</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-06-23 15:14:42</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">9-11</style></pages><abstract><style  face="normal" font="default" size="100%">Pooled data from the SECURE and VITAL global phase 3 multicenter trials have demonstrated the effectiveness of isavuconazole in the treatment of invasive aspergillosis in patients with renal insufficiency. Other intravenous triazole antifungals are contraindicated in these patients. Dose adjustment of isavuconazole is not needed.</style></abstract><number><style face="normal" font="default" size="100%">48</style></number><volume><style face="normal" font="default" size="100%">15</style></volume></record></records></xml>